S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
NASDAQ:NEO

NeoGenomics (NEO) Stock Forecast, Price & News

$12.42
+0.11 (+0.89%)
(As of 09/27/2023 ET)
Compare
Today's Range
$12.31
$12.63
50-Day Range
$12.15
$17.54
52-Week Range
$6.00
$20.54
Volume
501,944 shs
Average Volume
970,827 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.18

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
54.4% Upside
$19.18 Price Target
Short Interest
Bearish
4.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of NeoGenomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.44) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

415th out of 976 stocks

Testing Laboratories Industry

1st out of 1 stocks


NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Price History

NEO Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
4 Analysts Have This to Say About NeoGenomics
NeoGenomics Inc (NG9.BE)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
NeoGenomics Reports Second Quarter 2023 Results
BTIG Reaffirms Their Buy Rating on NeoGenomics (NEO)
Craig-Hallum Reaffirms Their Buy Rating on NeoGenomics (NEO)
NEO - NeoGenomics, Inc.
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$19.18
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+54.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-144,250,000.00
Pretax Margin
-22.75%

Debt

Sales & Book Value

Annual Sales
$551.62 million
Book Value
$7.90 per share

Miscellaneous

Free Float
125,894,000
Market Cap
$1.58 billion
Optionable
Optionable
Beta
1.08

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 60)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Vishal Sikri (Age 47)
    Pres of Advanced Diagnostics Division
    Comp: $1.21M
  • Mr. Warren Stone (Age 50)
    Pres of Clinical Division
    Comp: $722.79k
  • Ms. Cynthia J. Dieter (Age 48)
    Chief Accounting Officer
  • Mr. Greg Sparks
    Chief Technology Officer
  • Ms. Kendra Sweeney
    VP of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 39)
    Gen. Counsel & Corp. Sec.
  • Mr. Hutan Hashemi J.D. (Age 44)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

11 analysts have issued 1-year price targets for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $19.18 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 at the start of the year. Since then, NEO shares have increased by 34.4% and is now trading at $12.42.
View the best growth stocks for 2023 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, August, 8th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.06. The medical research company had revenue of $146.92 million for the quarter, compared to analysts' expectations of $138.22 million. NeoGenomics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 6.36%.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of -$0.28--$0.23 for the period, compared to the consensus earnings per share estimate of -$0.36. The company issued revenue guidance of $565.00 million-$575.00 million, compared to the consensus revenue estimate of $562.42 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (5.17%), State Street Corp (3.86%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.05%), Schroder Investment Management Group (1.56%) and Northern Trust Corp (1.24%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $12.42.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.58 billion and generates $551.62 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,100 workers across the globe.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -